PEG & ADCs
- Three ADCs Expected To Be Approved In 2024-2025
- Antibody-drug Conjugates (ADCs) - Approvals by FDA/EMA/NMPA/PMDA
- FDA Approved Antibody-Drug Conjugates (ADCs) By 2025
- Dual-Payload ADCs: A Revolutionary Leap in Targeted Cancer Therapy
- Antibody–Drug Conjugate Payloads: MMAE & MMAF
- Enhertu (Trastuzumab Deruxtecan): Magic ADC Drug
- The Bystander Effect of ADCs
- Topoisomerase I inhibitors Based ADCs: SN-38 & DXd
- What Are ADC Payloads?
- What Are ADC Linkers: Cleavable vs. Non-Cleavable Linkers